Abstract:In 1992, in an effort to bring novel drugs to market more quickly and meet patient needs in a timely manner, the US Food and Drug Administration (FDA) pioneered an accelerated approval initiative on the basis of surrogate endpoints that are reasonably predictive of clinical benefit for the treatment of serious or life-threatening diseases. 1 US Food and Drug AdministrationAccelerated approval program. https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-programDate accessed: October 24, 2023 Google Scholar By contrast to regular approval, accelerated approval requires post-market confirmatory clinical trials to establish the clinical benefit of the drug, then a decision is made as to whether the approval should be converted to a traditional approval or whether the drug should be withdrawn from the market. 2 US Food and Drug AdministrationExpedited programs for serious conditions––drugs and biologics. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-and-biologicsDate accessed: October 24, 2023 Google Scholar In the past 3 years, this expedited pathway has attracted extensive criticism, including failure to complete confirmatory clinical trials in a timely manner, 3 Fashoyin-Aje LA Mehta GU Beaver JA Pazdur R The on- and off-ramps of oncology accelerated approval. N Engl J Med. 2022; 387: 1439-1442 Crossref PubMed Scopus (33) Google Scholar , 4 Gyawali B Kesselheim AS Ross JS The accelerated approval program for cancer drugs—finding the right balance. N Engl J Med. 2023; 389: 968-971 Crossref PubMed Scopus (9) Google Scholar use of surrogate endpoints (eg, progression-free survival) in confirmatory clinical trials, 5 Parikh RB Hubbard RA Wang E et al. Exposure to US cancer drugs with lack of confirmed benefit after US Food and Drug Administration accelerated approval. JAMA Oncol. 2023; 9: 567-569 Crossref PubMed Scopus (6) Google Scholar and failure to withdraw drugs quickly from the markets when they have been shown to not have clinical benefit. 6 Akhade A Sirohi B Gyawali B Global consequences of the US FDA's accelerated approval of cancer drugs. Lancet Oncol. 2022; 23: 201-203 Summary Full Text Full Text PDF PubMed Scopus (10) Google Scholar Concerns have also been raised that cancer drugs given accelerated approval by the FDA could lead to difficult decisions in other countries, especially in some low-income and middle-income countries that do not have their own regulatory agencies or that have weak regulatory capacity. 6 Akhade A Sirohi B Gyawali B Global consequences of the US FDA's accelerated approval of cancer drugs. Lancet Oncol. 2022; 23: 201-203 Summary Full Text Full Text PDF PubMed Scopus (10) Google Scholar , 7 Cramer A Sørup FKH Christensen HR Petersen TS Karstoft K Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU?. Lancet Oncol. 2023; 24: e385-e394 Summary Full Text Full Text PDF PubMed Scopus (3) Google Scholar

Real-world evidence and regulatory drug approval

Current Regulatory Status in China of Drugs Withdrawn from the US FDA Accelerated Pathway: Implications for Regulation Globally

Examining the Use of Real‐World Evidence in the Regulatory Process

Real-world evidence to support regulatory submissions: A landscape review and assessment of use cases

Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment

Use of real‐world evidence in regulatory decisions for rare diseases in the United States—Current status and future directions

Expanded Access as a source of real‐world data: An overview of FDA and EMA approvals

The Use of Real-World Data/evidence in Regulatory Submissions.

Use of Real‐World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design

Reality check: Real-world evidence to support therapeutic development in hematologic malignancies

A systematic review of real-world evidence (RWE) supportive of new drug and biologic license application approvals in rare diseases

New drug approvals in oncology

Using Real-World Evidence To Support The Fda Regulatory Approval: Methodological Considerations

Real-World Evidence: A Primer

[The role of real-world evidence for the study of rare diseases epidemiology and the post-marketing evaluation of orphan drugs]

Real-World Evidence Should Be Used in Regulatory Decisions About New Pharmaceutical and Medical Device Products for Diabetes

Is Canada Moving towards a More Agile Regulatory Approval and Reimbursement Process with a Shifting Role for Real-World Evidence (RWE) for Oncology Drugs?

Use of Real-World Data and Real-World Evidence in Rare Disease Drug Development: A Statistical Perspective

Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective

FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis

Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making